Dupilumab Administration in the Patient with Severe Eosinophilic Esophagitis Combined with T2-Associated Diseases: Case Study

Background. T2-associated diseases such as eosinophilic esophagitis (EoE), atopic dermatitis, and bronchial asthma have common pathogenetic mechanism — hyperproduction of interleukins (IL) 4, 5 and 13. Standard therapy for severe forms of EoE and comorbid T2 pathologies may be ineffective. Dupilumab (monoclonal antibody to the IL-4R receptor) selectively blocks IL-4/IL-13 signaling pathways. Thus, this medication can be considered as the promising treatment option for EoE with refractory course and multiple atopic conditions. Case description. Child with EoE complicated by esophageal stenosis, comorbid atopic dermatitis, and allergic rhinitis, with ineffective standard therapy (proton pump inhibitors, topical corticosteroids, and elimination diet), was prescribed dupilumab, 300 mg every 2 weeks (child’s weight of 34 kg, total dosage was 800 g). Dysphagia and abdominal pains resolved 3 months after biological therapy onset. The patient has started eating solid food, his appetite has improved. Normalization of physical development indicators (HAZ, BAZ) was noted. Remission of atopic dermatitis was achieved during the therapy, and endoscopic esophageal dilation was avoided. No side effects were reported due to dupilumab therapy. Conclusion. Dupilumab significantly reduces eosinophilic infiltration of esophageal mucosa and symptoms severity in the patient with severe EoE combined with T2-associated diseases. This medication opens new possibilities for personalized therapy of patients with EoE via modulating effect on genetically determined T2-inflammation.

1. Amil-Dias J, Oliva S, Papadopoulou A, et al. Diagnosis and management of eosinophilic esophagitis in children: An update from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2024;79(2):394–437. doi: https://doi.org/10.1002/jpn3.12188

2. Eozinofil’nyi ezofagit: Clinical guidelines. 2024. (In Russ). Доступно по: https://www.pediatr-russia.ru/information/klinrek/proekty-klinicheskikh-rekomendatsiy/Клин_рекомендации_ЭозЭ_27.02.24.pdf. Ссылка активна на 19.07.2025.

3. Vinit C, Dieme A, Courbage S, et al. Eosinophilic esophagitis: Pathophysiology, diagnosis, and management. Arch Pediatr. 2019;26(3):182–190. doi: https://doi.org/10.1016/j.arcped. 2019.02.005

4. Simon D, Page B, Vogel M, et al. Evidence of an abnormal epithelial barrier in active, untreated and corticosteroid-treated eosinophilic esophagitis. Allergy. 2018;73(1):239–247. doi: https://doi.org/10.1111/all.13244

5. Ruffner MA, Cianferoni A. Phenotypes and endotypes in eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2020;124(3):233–239. doi: https://doi.org/10.1016/j.anai.2019.12.011

6. Blanchard C, Wang N, Stringer KF, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest. 2006;116(2):536–547. doi: https://doi.org/10.1172/JCI26679

7. Oliva S, Dias JA, Rea F, et al. Characterization of Eosinophilic Esophagitis From the European Pediatric Eosinophilic Esophagitis Registry (pEEr) of ESPGHAN. J Pediatr Gastroenterol Nutr. 2022;75(3):325–333. doi: https://doi.org/10.1097/MPG.0000000000003530

8. Warners MJ, Oude Nijhuis RAB, de Wijkerslooth LRH, et al. The natural course of eosinophilic esophagitis and long-term consequences of undiagnosed disease in a large cohort. Am J Gastroenterol. 2018;113(6):836–844. doi: https://doi.org/10.1038/s41395-018-0052-5

9. Kim JP, Weingart G, Hiramoto B, et al. Clinical outcomes of adults with eosinophilic esophagitis with severe stricture. Gastrointest Endosc. 2020;92(1):44–53. doi: https://doi.org/10.1016/j.gie.2020.01.015

10. Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013;145(6):1230–1236.e62. doi: https://doi.org/10.1053/j.gastro.2013.08.015

11. Papadopoulou A, Koletzko S, Heuschkel R, et al. Management guidelines of eosinophilic esophagitis in childhood. J Pediatr Gastroenterol Nutr. 2014;58(1):107–118. doi: https://doi.org/10.1097/MPG.0b013e3182a80be1

12. Dellon ES, Woosley JT, Arrington A, et al. Rapid Recurrence of Eosinophilic Esophagitis Activity After Successful Treatment in the Observation Phase of a Randomized, Double-Blind, Double-Dummy Trial. Clin Gastroenterol Hepatol. 2020;18(7):1483–1492.e2. doi: https://doi.org/10.1016/j.cgh.2019.08.050

13. Chang NC, Thakkar KP, Ketchem CJ, et al. A Gap in Care Leads to Progression of Fibrosis in Eosinophilic Esophagitis Patients. Clin Gastroenterol Hepatol. 2022;20(8):1701–1708.e2. doi: https://doi.org/10.1016/j.cgh.2021.10.028

14. Lucendo AJ, Molina-Infante J, Arias Á, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017;5(3):335–358. doi: https://doi.org/10.1177/2050640616689525

15. Chehade M, Dellon ES, Spergel JM, et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. N Engl J Med. 2024;390(24):2239–2251. doi: https://doi.org/10.1056/NEJMoa2312282

16. Patel SA. Real-world efficacy of dupilumab in four cases of paediatric-onset fibrostenotic eosinophilic esophagitis. Clin Exp Pharmacol Physiol. 2024;51(8):e13903. doi: https://doi.org/10.1111/1440-1681.13903

17. Gangadharan Nambiar G, Rahhal R, Davis BP, et al. Refractory Pediatric Fibrostenotic Eosinophilic Esophagitis Treated With Dupilumab. ACG Case Rep J. 2022;9(11):e00887. doi: https://doi.org/10.14309/crj.0000000000000887

18. Hudgens S, Evans C, Phillips E, Hill M. Psychometric validation of the Dysphagia Symptom Questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension. J Patient Rep Outcomes. 2017;1(1):3. doi: https://doi.org/10.1186/s41687-017-0006-5

19. Ghezzi M, Pozzi E, Abbattista L, et al. Barrier Impairment and Type 2 Inflammation in Allergic Diseases: The Pediatric Perspective. Children (Basel). 2021;8(12):1165. doi: https://doi.org/10.3390/children8121165

20. Meng J, Xiao H, Xu F, et al. Systemic barrier dysfunction in type 2 inflammation diseases: perspective in the skin, airways, and gastrointestinal tract. Immunol Res. 2025;73(1):60. doi: https://doi.org/10.1007/s12026-025-09606-9

21. Munoz-Persy M, Lucendo AJ. Treatment of eosinophilic esophagitis in the pediatric patient: an evidence-based approach. Eur J Pediatr. 2018;177(5):649–663. doi: https://doi.org/10.1007/s00431-018-3129-7

22. Philpott H, Dellon ES. The role of maintenance therapy in eosinophilic esophagitis: who, why, and how? J Gastroenterol. 2018;53(2): 165–171. doi: https://doi.org/10.1007/s00535-017-1397-z

23. Alexander R, Kassmeyer B, Lennon R, et al. EoE Recurrence on PPI Maintenance Therapy: You Do Not Know if You Do Not Look! Dig Dis Sci. 2024;69(11):4048–4052. doi: https://doi.org/10.1007/s10620-024-08676-3

24. Thel HL, Borinsky SA, LaFata SS, et al. Histologic Response or Endoscopic Normalization After Initial Treatment for Eosinophilic Esophagitis in Children Leads to Less Fibrostenosis over Long-Term Follow-Up. Dig Dis Sci. 2025;70(4):1428–1434. doi: https://doi.org/10.1007/s10620-025-08914-2

25. García-Compeán D, González-Moreno EI, GonzálezGonzález JA, et al. Lack of compliance with consensus recommendations on the diagnosis of eosinophilic esophagitis (EoE) in published prevalence studies. A clinical and systematic review. J Dig Dis. 2016;17(10):660–669. doi: https://doi.org/10.1111/1751-2980.12400

26. Mongkonsritragoon W, Varre A, Beydoun S, et al. Factors associated with treatment response in eosinophilic esophagitis patients: Experience from a pediatric tertiary care center. Allergy Asthma Proc. 2025;46(2):135–143. doi: https://doi.org/10.2500/aap.2025.46.2401

27. Bredenoord AJ, Dellon ES, Schlag C, et al. Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trial. Expert Rev Gastroenterol Hepatol. 2025;19(2):197–209. doi: https://doi.org/10.1080/17474124.2025.2461516

28. Tomás-Pérez M, Domenech-Witek J, Ávila-Castellano MR, et al. Position Paper on the Treatment of Eosinophilic Esophagitis With Dupilumab. J Investig Allergol Clin Immunol. 2025;35(3):170–178. doi: https://doi.org/10.18176/jiaci.1038.